Skip to main content

The independent medical news service

01-02-2023 | Oncology | News | Article

FDA approves elacestrant, adds indication for pembrolizumab

Details of these breast and lung cancer decisions available here

20-01-2023 | Oncology | News | Article

IL-7 genetic variant linked to ICI toxicity

A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.

18-01-2023 | Oncology | News | Article

Veliparib addition may improve PFS for metastatic TNBC patients with BRCA-like phenotype

Use of veliparib during cisplatin chemotherapy may help improve progression-free survival in patients with metastatic triple-negative breast cancer displaying biomarker characteristics similar to those seen in BRCA1/2 mutation-positive disease, suggest findings from a phase 2 trial.

12-12-2022 | Oncology | News | Article

Phase 3 data support add-on capivasertib in people with AI-resistant advanced breast cancer

The addition of the AKT inhibitor capivasertib to fulvestrant significantly prolongs the progression-free survival of people with hormone receptor-positive, HER2-negative advanced breast cancer that is resistant aromatase inhibitors, indicate the results of CAPItello-291.

09-12-2022 | Oncology | News | Article

Encouraging data for neoadjuvant T-DXd in HER2-low early breast cancer

Trastuzumab deruxtecan has demonstrated promising efficacy and tolerability in the neoadjuvant treatment of HER2-low, hormone receptor-positive early breast cancer in the TRIO-US B-12 TALENT trial.

09-12-2022 | Oncology | News | Article

Next-generation oral SERD shows promise in ER-positive, advanced breast cancer

Treatment with the novel oral selective estrogen receptor degrader camizestrant significantly improves progression-free survival versus fulvestrant in patients with pretreated, estrogen receptor-positive, HER2-negative advanced breast cancer, shows a phase 2 study.